 HC Wainwright reaffirmed their buy rating on shares of Marinus Pharmaceuticals NASDAQ:MRNS in a report issued on Tuesday, AnalystRatings.com reports. HC Wainwright currently has a 9.00 price target on the biopharmaceutical companys stock, up from their previous price target of 6.00. Several other research analysts have also commented on the company. BidaskClub upgraded Marinus Pharmaceuticals ... 